DOP2020000010A - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
DOP2020000010A
DOP2020000010A DO2020000010A DO2020000010A DOP2020000010A DO P2020000010 A DOP2020000010 A DO P2020000010A DO 2020000010 A DO2020000010 A DO 2020000010A DO 2020000010 A DO2020000010 A DO 2020000010A DO P2020000010 A DOP2020000010 A DO P2020000010A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical compositions
valsartan
atorvastatin
metformin
processes
Prior art date
Application number
DO2020000010A
Other languages
English (en)
Inventor
Yantao Zhang Tony
Carl Allgeier Matthew
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2020000010A publication Critical patent/DOP2020000010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones sólidas de dosis fija oral de metformina, atorvastatina y valsartán, o sales aceptables desde el punto de vista farmacéutico de estos, procesos para la preparación de estas y el uso de la composición para tratar ciertas enfermedades.
DO2020000010A 2017-07-17 2020-01-15 Composiciones farmacéuticas DOP2020000010A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533332P 2017-07-17 2017-07-17
US201762538936P 2017-07-31 2017-07-31
PCT/US2018/041378 WO2019018155A1 (en) 2017-07-17 2018-07-10 PHARMACEUTICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
DOP2020000010A true DOP2020000010A (es) 2020-02-28

Family

ID=63036446

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000010A DOP2020000010A (es) 2017-07-17 2020-01-15 Composiciones farmacéuticas

Country Status (24)

Country Link
US (2) US11376223B2 (es)
EP (1) EP3654955A1 (es)
JP (1) JP6854384B2 (es)
KR (1) KR102409102B1 (es)
CN (1) CN110913843B (es)
AU (1) AU2018301924B2 (es)
BR (1) BR112019028278A2 (es)
CA (1) CA3069948C (es)
CL (1) CL2020000120A1 (es)
CO (1) CO2019015099A2 (es)
CR (1) CR20190577A (es)
DO (1) DOP2020000010A (es)
EC (1) ECSP20003493A (es)
IL (1) IL272044A (es)
JO (1) JOP20200005A1 (es)
MA (1) MA49625A (es)
MY (1) MY198062A (es)
PE (1) PE20200174A1 (es)
PH (1) PH12020500120A1 (es)
SA (1) SA520410976B1 (es)
SG (1) SG11201912482WA (es)
UA (1) UA125535C2 (es)
WO (1) WO2019018155A1 (es)
ZA (1) ZA201908550B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125535C2 (uk) * 2017-07-17 2022-04-13 Елі Ліллі Енд Компані Фармацевтичні композиції

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
JP4523153B2 (ja) 1998-03-19 2010-08-11 ブリストル−マイヤーズ スクイブ カンパニー 易溶性薬物の二層性放出制御送達システムおよび方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CN1688341A (zh) * 2002-08-08 2005-10-26 三共株式会社 降低血脂的药物组合物
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
PL2120878T3 (pl) 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
WO2008146178A2 (en) * 2007-05-30 2008-12-04 Wockhardt Research Centre A novel tablet dosage form
MX2013000824A (es) 2010-07-21 2013-10-28 Nucitec Sa De Cv Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US9572784B2 (en) * 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
DK2830618T3 (en) * 2012-03-30 2016-10-03 Dae Woong Pharma A pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
BR102013028883A2 (pt) 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
WO2016040462A2 (en) 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
UA125535C2 (uk) * 2017-07-17 2022-04-13 Елі Ліллі Енд Компані Фармацевтичні композиції

Also Published As

Publication number Publication date
ECSP20003493A (es) 2020-08-31
CN110913843A (zh) 2020-03-24
US20210137842A1 (en) 2021-05-13
NZ760868A (en) 2023-09-29
US20220287978A1 (en) 2022-09-15
BR112019028278A2 (pt) 2020-07-14
MY198062A (en) 2023-07-31
US11918692B2 (en) 2024-03-05
PE20200174A1 (es) 2020-01-24
CA3069948A1 (en) 2019-01-24
CA3069948C (en) 2022-05-17
UA125535C2 (uk) 2022-04-13
EP3654955A1 (en) 2020-05-27
SA520410976B1 (ar) 2023-03-23
IL272044A (en) 2020-03-31
SG11201912482WA (en) 2020-02-27
JP2020527147A (ja) 2020-09-03
KR102409102B1 (ko) 2022-06-16
US11376223B2 (en) 2022-07-05
CL2020000120A1 (es) 2020-07-17
AU2018301924B2 (en) 2021-07-29
PH12020500120A1 (en) 2020-09-28
JP6854384B2 (ja) 2021-04-07
CO2019015099A2 (es) 2020-01-17
AU2018301924A1 (en) 2019-12-19
WO2019018155A1 (en) 2019-01-24
MA49625A (fr) 2020-05-27
CR20190577A (es) 2020-01-29
JOP20200005A1 (ar) 2020-01-14
CN110913843B (zh) 2022-09-13
KR20200015758A (ko) 2020-02-12
ZA201908550B (en) 2024-06-26

Similar Documents

Publication Publication Date Title
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201692298A1 (ru) Производные карбоксамидов
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
UY36124A (es) Derivados de carboxamida
EA201890532A1 (ru) Новые аннелированные бензамиды
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
CO2020005885A2 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
DOP2020000010A (es) Composiciones farmacéuticas
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
UY38133A (es) Nuevos inhibidores de cdk8/19
EA201992754A1 (ru) Фармацевтические композиции
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
WO2019240700A3 (en) Oral pharmaceutical compositions of mesalazine